Screener
Dianthus Therapeutics DNTH Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock under employee stock purchase plan | 120 | 129 |
| Proceeds from exercise of warrants and pre-funded warrants | 1 | 1 |
| Net cash provided by financing activities | 739,410 | 161 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 576,581 | (12,675) |
| Cash, cash equivalents and restricted cash, beginning of period | 51,254 | 23,022 |
| Cash, cash equivalents and restricted cash, end of period | $627,835 | $10,347 |
| Supplemental Disclosure | ||
| Cash and cash equivalents | $627,667 | $10,116 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's net change in cash?
- Dianthus Therapeutics (DNTH) reported net change in cash of $576.58M in Q1 2026.
- How has Dianthus Therapeutics's net change in cash changed year-over-year?
- Dianthus Therapeutics's net change in cash increased by 4649.0% year-over-year, from -$12.68M to $576.58M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Dianthus Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude